Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
© 2026 Copyright Enamine
Back
Product details:
CAS
2186700-33-2
Purity
95%
Ervogastat is a first-in-class DGAT2 inhibitor and is currently in Phase 2 for the treatment of NASH or improvement of liver fibrosis. This compound has demonstrated potent reversible inhibition against DGAT2 (IC50 = 2.8 nM) and selectivity (<50 uM against DGAT1) and no appreciable off-target activity in a CEREP panel.
Properties
Name
Ervogastat
Smiles
CCOC=1C=CC=NC1OC=2C=NC=C(C2)C=3N=CC(=CN3)C(=O)N[C@H]4CCOC4
Targets
Please log in to see this information
Target name
Target pX
Target action
doi
SDS
PF-0686571
No data available
The compound has purity validated by NMR and/or LCMS methods.
1 mg
$POA
2 mg
$POA
5 mg
$POA
10 mg
$POA
15 mg
$POA
20 mg
$POA
25 mg
$POA
30 mg
$POA
35 mg
$POA
40 mg
$POA
45 mg
$POA
50 mg
$POA
75 mg
$POA
100 mg
$POA
Quantity
1
Total amount
$ 0
PF-0686571
No data available
The compound has purity validated by NMR and/or LCMS methods.
Target activity features
It should be emphasized that the product may be active against a larger number of targets than shown on the card. The information represented here refers to the targets with the largest value of pX or the targets with ΔpX less than 1.5 from the largest pX value.